{"id":"W4393988846","doi":"10.1158/1538-7445.am2024-ct253","title":"Abstract CT253: Results from KEYNOTE-B99: Phase 2 study of first-line (1L) pembrolizumab (pembro) plus investigational agents and chemotherapy (chemo) for extensive-stage small-cell lung cancer (ES-SCLC)","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Kingston Health Sciences Centre","funders":"","keywords":"Pembrolizumab; Medicine; Investigational Drugs; Chemotherapy; Cancer; Oncology; Stage (stratigraphy); Lung cancer; Internal medicine; Clinical trial; Immunotherapy; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001949103,0.002071027,0.002063504,0.000487011,0.0006516792,0.001188555,0.001607341,0.001995771,0.01373118],"category_scores_gemma":[0.001077794,0.0006390364,0.001524135,0.0006682334,0.001016178,0.00115184,0.0005602925,0.004083,0.002483073],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001223019,"about_ca_system_score_gemma":0.002603016,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001374929,"about_ca_topic_score_gemma":0.004163005,"domain_scores_codex":[0.999482,0.0002499699,0.00003308147,0.00008652698,0.00004816438,0.0001002947],"domain_scores_gemma":[0.999103,0.0001237942,0.0001466807,0.00007230719,0.0000553341,0.0004988411],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8911004,0.03428973,0.003047185,0.001046288,0.001250312,0.00027059,0.000099588,0.001271017,0.03058611,0.0001846646,0.008449389,0.02840469],"study_design_scores_gemma":[0.7576853,0.2242537,0.009704796,0.00007040977,0.000876873,0.0002887992,0.00003895902,0.0004692688,0.003222653,0.0001617403,0.003191551,0.00003612279],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9649242,0.004835955,0.0008453675,0.001018499,0.0002612657,0.006329822,0.0148894,0.0002865488,0.006608873],"genre_scores_gemma":[0.9560478,0.002859834,0.002216921,0.001882018,0.0003032272,0.005351732,0.02381101,0.00008266149,0.007444698],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01373118,"threshold_uncertainty_score":0.04593539,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1650868233839156,"score_gpt":0.4784425243929593,"score_spread":0.3133557010090437,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}